SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin resumes sales of Generic Fortamet

19 Apr 2012 Evaluate

Pharma Major, Lupin has been granted its request to stay the preliminary injunction by the US Court of Appeals for the Federal Circuit that had earlier barred sales of its generic of Shionogi’s Fortamet tablets. Lupin’s Metformin Hydrochloride tablets are the AB-rated generic equivalent of Fortamet 500 mg and 1000 mg tablets. The company has resumed sales of its product.

Lupin had earlier received final approval for its Metformin tablets from the US FDA and had launched the product in September, 2011. In December, 2011 Shionogi’s request for a preliminary injunction had been granted and had blocked Lupin from further sales of the product.

Fortamet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The annual US sales for Fortamet stood at $70.2 million for the twelve months ending December 2011, as per IMS Health data.

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2245.65 -132.25 (-5.56%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×